Justin Delgado is husband to Kacie Doyle-Delgado, diagnosed at age 11. After more than a decade together, he considers himself to be an expert carb counter and Dexcom inserter. He graduated with his Master of Science in Finance from the University of Utah in 2013 and has been working in commercial banking since then. He attended his first Friends for Life conference in 2015 and is looking forward to volunteering with the teens.
March 17, 2003
Blood Tests and Insulin Injections, Insulin Pumps
Question from Columbus, Georgia, USA:
Before starting a pump with NovoLog, my daughter developed lipoatrophy on the right side of her naval. After switching to the pump, we were advised to begin switching sides, keeping away from the atrophied area, as well as spacing the infusion sites in a clock pattern for extra precaution. Since then, she has developed another lipoatrophy site above the older one (even though we stayed clear of the first one) and very recently has shown the beginnings of another site right above the other two sites at her first rib. This last site had no pump infusion sites remotely near it, yet it continues to develop. Even though we swap sides and change sites regularly, her doctor seems to think that her problem stems from her being right handed and is using more force on that side when using her infusion injection device. We feel that it is not the case since she always uses both hands to release the infusion injector buttons, not just one. This would not explain the fact that there is another site developing right at her rib cage. We're even advising our daughter to move her infusion site around to the back side of her waist where adults have their "spare tires" to keep a longer rotation of the infusion needle. Is there another explanation for these "dents"? Is this so new that it hasn't been fully explored yet?
I have not had to deal with lipoatrophy in a long time. Maybe she is particularly vulnerable to it. I don’t have the same experience with NovoLog in other patients, but it is new enough that the data base is smaller than other rapid insulins particularly regarding lipoatrophy.